Interview with Charles Woler, CEO, Endotis Pharma
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
Address: 102 avenue Gaston Roussel
93230 Romainville France
Tel: +33 (0)1 48 46 43 91
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs (SGDs, heparin / heparan sulphate mimetics) for use in thrombosis, oncology and a range of other indications with several potential blockbuster drugs. Founded in february 2003, Endotis is a privately held company which currently employs 34 people between sites in Paris and Lille.
Endotis’ business model is to develop antithrombotic drugs in man until proof-of principle (oral anticoagulants) or Phase IIb dose finding (parenteral antithrombotics), and then partner them; while in other therapeutic areas such as oncology, partnering could take place once proof of concept in animal is demonstrated.
Endotis has three main areas of activity:
– A derisked thrombosis franchise of heparin-derived synthetic oligosaccharides
– An oncology pipeline consisting of heparan sulfate mimetics
– A drug discovery engine: unique know-how from discovery to manufacturing of small-glyco drugs (SGDs) with range of applications
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
Bernard Fraisse of Fareva, France’s leading CMO, discusses growth, international expansion, loyalty to France, dedication to clients, and commitment to providing high quality products. Many have predicted that pharma manufacturing…
Marc Alexander Burmeister of B. Braun France speaks about the country’s role as a production hub for B. Braun’s global operations, its 2020 strategy to reach USD 200 million in…
Jean-Paul Berthomé, the CEO of Laboratoires Expanscience, talks about the company’s global ambitions, flagship products and strategies to tackle challenges in emerging economies. With a presence in highly saturated markets,…
Shire France’s General Manager, Andrew Obenshain, speaks optimistically about the leading market conditions in France, the corporate culture of a multinational company in a niche market, and building a rapport…
As CEO of the newly formed government agency Business France, Muriel Pénicaud is passionate about championing French innovation and creativity, particularly in life sciences. She tells us about her organization’s…
The dynamic Director of ESCP Europe’s Master in Biopharmaceutical Management talks about being the reference higher education institution for programs catering to the biopharma sector, plans for more international visibility,…
Thierry Guillot, president of Chugai Pharma France, talks about the challenge of transitioning from a small organization, which revolved around one main product into a larger entity capable of delivering…
CreaPharm Group’s CEO, Eric Placet, discusses the creation of his company, ambitions for growth, and the lessons learned throughout his leadership. He also emphasizes the relevance of the size of…
LEO Pharma is expanding its global presence and continuing its leading role in the number of skin disease patients treated and in thrombosis care. Head of the company’s French affiliate,…
With over 15 years of expertise in external sterilization services for medical devices and surgical instruments, Sterience has successfully positioned itself as the market leader in France. Directing the company…
Boston Scientific is raising the bar for medical devices and services in the field of cardiology and other pathologies, including Rhythm Management, Endoscopy, Urology Pelvic Health, and Neurostimulation. European President…
Vygon CEO, Stephane Regnault, shares the international strategy of one of the largest independent French medical device companies and their continuing commitment to quality. You are one of the few mid-sized…
See our Cookie Privacy Policy Here
